1-(4-chlorophenyl)piperazine, often abbreviated as **CPP**, is a chemical compound that has gained significant attention in research for its unique properties. Here's why it's important:
**1. A Versatile Research Tool:**
* **Pharmacological Actions:** CPP is a potent and selective antagonist of the 5-HT1A receptor. This means it blocks the action of serotonin at this specific receptor subtype. This makes it valuable for studying the role of 5-HT1A receptors in various brain functions and conditions.
* **Behavioral Effects:** CPP is known to induce a variety of behavioral changes in animal models, including anxiolytic (anti-anxiety), antidepressant, and anti-aggressive effects. This makes it a useful tool for understanding the mechanisms underlying these behaviors and for testing potential new treatments.
**2. Applications in Research:**
* **Neuroscience:** CPP is widely used in preclinical research to investigate the role of 5-HT1A receptors in various neurological and psychiatric conditions. This includes anxiety disorders, depression, schizophrenia, and drug addiction.
* **Drug Development:** CPP is a lead compound for the development of novel drugs targeting the 5-HT1A receptor. Its high affinity and selectivity make it an attractive candidate for creating more effective and safer treatments for various mental health disorders.
* **Understanding Neurotransmission:** CPP is a useful tool for studying the complex interplay of different neurotransmitters in the brain. By selectively blocking the 5-HT1A receptor, researchers can isolate its specific contribution to various physiological and behavioral processes.
**3. Importance for Understanding Brain Function:**
* **Serotonin System:** CPP helps researchers understand the intricate workings of the serotonin system, which plays a crucial role in regulating mood, cognition, sleep, and appetite. By studying the effects of CPP, researchers gain insights into the functions of specific serotonin receptors and their involvement in various brain processes.
* **Neurological and Psychiatric Disorders:** CPP is crucial for developing better treatments for neurological and psychiatric disorders. It helps researchers identify potential drug targets and develop novel medications that are more effective and have fewer side effects.
**Important Note:**
While CPP is a valuable research tool, it is **not approved for human use**. It is a powerful compound and should only be handled by trained professionals in a controlled laboratory setting.
**In Summary:**
1-(4-chlorophenyl)piperazine is a potent and selective antagonist of the 5-HT1A receptor, making it a valuable tool for research in various fields. Its unique properties allow researchers to explore the complex workings of the serotonin system, understand the mechanisms underlying various behaviors, and develop new drug targets for treating neurological and psychiatric disorders.
1-(4-chlorophenyl)piperazine: increases serotonin & decreases 5-hydroxyindoleacetic acid concentration in rat brain 6 hours after administration; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 97478 |
CHEMBL ID | 114478 |
SCHEMBL ID | 219742 |
MeSH ID | M0086691 |
Synonym |
---|
BB 0257092 |
nsc126708 |
nsc-126708 |
38212-33-8 |
IDI1_030583 |
1-(4-chlorophenyl)piperazine |
MAYBRIDGE4_000001 |
NCIOPEN2_003642 |
1-(4-chlorophenyl)piperazine, >=98.0% (gc) |
STK500344 |
AKOS000101158 |
CHEMBL114478 , |
pcpp |
bdbm50001897 |
1-(4-chloro-phenyl)-piperazine |
para-chlorophenylpiperazine |
AK-968/40173407 |
1-(para-chlorophenyl)piperazine |
piperazine, 1-(4-chlorophenyl)- |
unii-fmd47je5c3 |
nsc 126708 |
fmd47je5c3 , |
FT-0605700 |
SCHEMBL219742 |
FS-1226 |
1-(4-chlorophenyl)-piperazine |
4-(4-chlorophenyl)piperazine |
1-(4-chloro-phenyl)piperazine |
4(4-chlorophenyl)piperazine |
4-(4-chlorophenyl) piperazine |
4-chlorophenyl piperazine |
1-(4-chlorophenyl) piperazine |
1-(4-chloro-phenyl) piperazine |
n-(p-chlorophenyl)piperazine |
4-chloro phenylpiperazine |
4-chloro-phenyl-piperazine |
4-(4-chlorophenyl)-piperazine |
1-(4-chlorophenyl)piperazine # |
J-200027 |
acid ammonium purpurate, monohydrate |
mfcd00044823 |
DTXSID90191592 |
CS-W004758 |
AC-8980 |
p-cpp (1-(4-chlorophenyl)piperazine) |
p-cpp (1-(4-chlorophenyl)piperazine) 1.0 mg/ml in methanol |
SY014767 |
4-chlorophenylpiperazine |
Q7133612 |
AMY32508 |
p-chlorophenylpiperazine |
n-(4-chlorophenyl)piperazine |
PD076321 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 2.1600 | 0.0010 | 0.8835 | 9.9000 | AID6343 |
5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 2.1600 | 0.0010 | 0.8711 | 9.9000 | AID6343 |
Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 (µMol) | 15.0000 | 0.0002 | 1.4681 | 9.0000 | AID42027 |
5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 2.1600 | 0.0000 | 0.7411 | 9.9000 | AID6343 |
Beta-2 adrenergic receptor | Canis lupus familiaris (dog) | IC50 (µMol) | 70.0000 | 0.0001 | 2.4596 | 5.2000 | AID40701 |
5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 2.1600 | 0.0010 | 0.8835 | 9.9000 | AID6343 |
5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 2.1600 | 0.0010 | 0.8835 | 9.9000 | AID6343 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID493017 | Wombat Data for BeliefDocking | 1991 | Journal of medicinal chemistry, Dec, Volume: 34, Issue:12 | Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high-affinity sigma ligands. |
AID6343 | Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors. |
AID204444 | Binding affinity towards sigma receptor in guinea pig brain membranes using [3H]DTG as radioligand | 1991 | Journal of medicinal chemistry, Dec, Volume: 34, Issue:12 | Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high-affinity sigma ligands. |
AID42027 | Binding affinity for Beta-1 adrenergic receptor by displacing [3H]dihydroalprenolol, in partially purified membrane fractions from canine ventricular muscle in the presence of 1 uM zinterol | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents. |
AID40701 | Binding affinity towards Beta-2 adrenergic receptor by displacing [3H]dihydroalprenolol, in partially purified membrane fractions from canine lung tissue in the presence of 0.1 uM metoprolol | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 3 (75.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.38) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |